161 Azacytidine 75mg/m2 ×5 day in high-risk myelodysplastic syndromes and acute myeloid leukemia refractory/relapsed patients: Results from a single centre

J. Bergua, M.J. Arcos Carmona, J. Prieto Fernandez, C. Cabrera Silva, F. Carnicero, H. Fernandez-Leyva, M.L. Bengochea Miranda, M.L. Martín-Mateos, F. Izquierdo, E. Gil Esparraga, N. Bermejo Vega, M.J. García Blanco
  • Leukemia Research, May 2011, Elsevier
  • DOI: 10.1016/s0145-2126(11)70163-1

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1016/s0145-2126(11)70163-1

The following have contributed to this page: Dr Nuria Bermejo